[go: up one dir, main page]

MX2022010960A - Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. - Google Patents

Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides.

Info

Publication number
MX2022010960A
MX2022010960A MX2022010960A MX2022010960A MX2022010960A MX 2022010960 A MX2022010960 A MX 2022010960A MX 2022010960 A MX2022010960 A MX 2022010960A MX 2022010960 A MX2022010960 A MX 2022010960A MX 2022010960 A MX2022010960 A MX 2022010960A
Authority
MX
Mexico
Prior art keywords
mitigate
compositions
methods
use disorder
cannabinoid
Prior art date
Application number
MX2022010960A
Other languages
English (en)
Inventor
Ginger D Constantine
Original Assignee
Pleopharma L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pleopharma L L C filed Critical Pleopharma L L C
Priority claimed from PCT/US2021/020921 external-priority patent/WO2021178700A1/en
Publication of MX2022010960A publication Critical patent/MX2022010960A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar el síndrome de abstinencia de cannabis y otras afecciones relacionadas al cannabis, que incluyen trastorno por uso de cannabis en un sujeto, que comprenden administrar al sujeto que lo necesita una cantidad eficaz de un cannabinoide o una cantidad eficaz de un cannabinoide y una cantidad eficaz de un segundo agente activo, tal como gabapentina o un análogo de gabapentina.
MX2022010960A 2020-03-04 2021-03-04 Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. MX2022010960A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985097P 2020-03-04 2020-03-04
PCT/US2021/020921 WO2021178700A1 (en) 2020-03-04 2021-03-04 Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal

Publications (1)

Publication Number Publication Date
MX2022010960A true MX2022010960A (es) 2022-11-16

Family

ID=77555295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010960A MX2022010960A (es) 2020-03-04 2021-03-04 Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides.

Country Status (8)

Country Link
US (2) US11197846B2 (es)
EP (1) EP4114379A4 (es)
KR (1) KR20220163384A (es)
CN (1) CN115605195A (es)
AU (1) AU2021230540A1 (es)
CA (1) CA3170635A1 (es)
IL (1) IL296166A (es)
MX (1) MX2022010960A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296166A (en) 2020-03-04 2022-11-01 Pleopharma L L C Methods and preparations for treating cannabis use disorder and facilitating cannabinoid withdrawal
US12268659B2 (en) * 2020-03-04 2025-04-08 Pleopharma, Inc. Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal
CA3256368A1 (en) * 2022-06-03 2023-12-07 University Of Connecticut POLYCANNABINOID COMPOSITIONS AND THEIR USES

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
DE3305755A1 (de) 1983-02-19 1984-08-23 Gödecke AG, 1000 Berlin N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems
US4931283A (en) 1983-12-22 1990-06-05 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH06508371A (ja) 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
US5230897A (en) 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5360648A (en) 1993-06-24 1994-11-01 The Dow Chemical Company Pouch for packaging flowable materials
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6008383A (en) 1998-10-26 1999-12-28 University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol esters
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE60321318D1 (de) 2002-02-01 2008-07-10 Resolution Chemicals Ltd Gewinnung von delta-9 tetrahydrocannabinol
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
AU2008317336A1 (en) 2007-10-26 2009-04-30 The Scripps Research Institute Methods for treating substance dependence
ES2607209T3 (es) * 2009-02-06 2017-03-29 Egalet Ltd. Composiciones farmacéuticas resistentes al abuso
US9597340B2 (en) * 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US20180147141A1 (en) 2016-11-29 2018-05-31 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and gabapentin
WO2021178700A1 (en) 2020-03-04 2021-09-10 Pleopharma, L.L.C. Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal
IL296166A (en) 2020-03-04 2022-11-01 Pleopharma L L C Methods and preparations for treating cannabis use disorder and facilitating cannabinoid withdrawal

Also Published As

Publication number Publication date
KR20220163384A (ko) 2022-12-09
CA3170635A1 (en) 2021-09-10
US20220273612A1 (en) 2022-09-01
AU2021230540A1 (en) 2022-10-13
US11931334B2 (en) 2024-03-19
IL296166A (en) 2022-11-01
US20210275492A1 (en) 2021-09-09
EP4114379A1 (en) 2023-01-11
EP4114379A4 (en) 2024-01-17
US11197846B2 (en) 2021-12-14
CN115605195A (zh) 2023-01-13

Similar Documents

Publication Publication Date Title
BR112021022497A2 (pt) Composto, composição farmacêutica, uso da composição farmacêutica, e, métodos para prevenir ou tratar obesidade, diabetes, inflamação e disfunção erétil
CL2018001557A1 (es) Uso de un agente inhibidor de masp-2 que inhibe la activación del complemento dependiente de masp-2, para tratar un sujeto que padece de síndrome antifosfolipido catastrófico (safc). (solicitud divisional 201600908)
MX2022010960A (es) Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides.
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
CL2019000268A1 (es) Composición de cannabis.
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
MX2024012816A (es) Metodos para tratar y/o prevenir la enfermedad de injerto contra huesped y/o la hemorragia alveolar difusa y/o la enfermedad venooclusiva asociada al trasplante de celulas madre hematopoyeticas
MX379255B (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
BR112021025676A2 (pt) Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella
MX2022013081A (es) Compuestos para el tratamiento de sars.
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
ECSP20082339A (es) Moduladores de la expresión de apol1
AR097599A1 (es) Una composición que comprende extracto de guaçatonga y aroeira, su uso y un método para la prevención y/o tratamiento de señales causadas por el envejecimiento de la piel
BR112019001081A2 (pt) composição tópica, utilização de uma composição, métodos para o tratamento da hiperidrose em um indivíduo, composição e composição para a utilização
CO2022000270A2 (es) Inhibidores de enzimas
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2022008203A (es) Tratamiento de trastornos cutaneos.
MX2017004318A (es) Composiciones y metodos para el tratamiento y profilaxis de infecciones del sitio quirurgico.
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
MX2023009600A (es) Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias.
PH12017502145A1 (en) Composition and uses thereof
AR112291A1 (es) Composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncológico
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
MX2022013169A (es) Composiciones de spray nasal antiviral y virucida y metodos de tratamiento relacionados.